Q-omics provides the consensus-scored PRDX3P2 profile across patient tissues and cancer cell-line models. PRDX3P2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRDX3P2 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, PRDX3P2 RNA expression shows 15,089 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where PRDX3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDX3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDX3P2 survival associations across molecular data types. PRDX3P2 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDX3P2 RNA expression–survival associations across cancer types. High PRDX3P2 expression shows unfavorable associations in KIRC, THCA and PRAD, but favorable associations in STAD, UCS and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify KIRC as the clearest survival context for PRDX3P2 RNA expression.
This table summarizes PRDX3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for PRDX3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDX3P2 shows higher tumor expression in BLCA, COAD, STAD, UCEC, BRCA and KIRP. The BLCA box plot shows higher PRDX3P2 RNA expression in tumor versus normal tissue (log2 FC = +0.294, t-test p = .001).
This table shows molecular features associated with PRDX3P2 in patient tissues and cancer cell lines. In patient samples, PRDX3P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
